OncoMatch/Clinical Trials/NCT03458221
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Is NCT03458221 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Letrozole Oral Product and Bicalutamide Oral Product for recurrent ovarian cancer.
Treatment: Letrozole Oral Product · Bicalutamide Oral Product · Everolimus Oral Product · Itraconazole Oral Product — The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed beneficial in the select group of patients with a relevant predominantly active functional STP, in order to improve survival and maintain quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
WHO 0–2
Prior therapy
Must have received: systemic treatment — recurrent disease
Progressive disease after at least one prior line of systemic treatment for recurrent disease
Cannot have received: selected targeted drug
Previous use of the selected targeted drug as anti-cancer agent
Cannot have received: chemotherapy
chemotherapy naïve
Lab requirements
Kidney function
adequate renal function to start matched targeted therapy (according to the local clinician)
Liver function
adequate liver function to start matched targeted therapy (according to the local clinician)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify